{"id":"W2561214156","doi":"10.1182/blood.v118.21.4437.4437","title":"A Canadian Expanded Access Trial of Oral Nilotinb in Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Novartis (Canada); St. John’s Health Sciences Centre; Jewish General Hospital; McMaster University Medical Centre; Capital District Health Authority; Health Sciences Centre; Windsor Regional Hospital; Ottawa Hospital; London Health Sciences Centre; Brampton Civic Hospital; St. Paul's Hospital; Hôpital Maisonneuve-Rosemont; University of British Columbia; McGill University; McGill University Health Centre; University of Ottawa; Victoria Hospital; Hôpital de l'Enfant-Jésus","funders":"","keywords":"Nilotinib; Medicine; Discontinuation; Internal medicine; Adverse effect; Imatinib; Rash; Imatinib mesylate; Myeloid leukemia; Phases of clinical research; Cytopenia; Surgery; Gastroenterology; Clinical trial; Bone marrow","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007812469,0.0007727966,0.0009842068,0.0001833279,0.0006398342,0.0003926943,0.0005506321,0.0004651093,0.003447611],"category_scores_gemma":[0.0005632296,0.0002096403,0.0004155562,0.0003785977,0.0005703546,0.0002690289,0.0003534073,0.001141945,0.0003099027],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00325289,"about_ca_system_score_gemma":0.005909351,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.1041782,"about_ca_topic_score_gemma":0.3027859,"domain_scores_codex":[0.9996955,0.00009945451,0.00001132755,0.0000389419,0.0000772753,0.00007749027],"domain_scores_gemma":[0.9995751,0.00003661344,0.00005964814,0.00001218137,0.00005361065,0.0002628272],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7846375,0.02010179,0.03886673,0.001271755,0.002190758,0.0005231806,0.0005201814,0.001424747,0.02071403,0.0006546138,0.01494339,0.1141512],"study_design_scores_gemma":[0.6328878,0.1601296,0.1882547,0.0001308563,0.00103386,0.0004142202,0.0002187637,0.002066467,0.001764913,0.0002000104,0.01281768,0.00008117593],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.990892,0.002594243,0.000105395,0.0004835784,0.00004551619,0.001230913,0.001109037,0.00002348028,0.003516003],"genre_scores_gemma":[0.9939108,0.001376595,0.0003977188,0.000636458,0.00006394407,0.0004801027,0.001295808,0.000005566521,0.00183307],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8958218,"threshold_uncertainty_score":0.2071436,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0408920691426776,"score_gpt":0.3157582836705189,"score_spread":0.2748662145278413,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}